|
|
|
|
|
Albuterol: profile and news
Barrier Therapeutics to Present Data on Vusion(TM) and Sebazole(TM ... Mar 3, 2006 TODAY ON PHARMALIVE.COM Mar 3, 2006 Acne and Wrinkles: Double Trouble? Mar 1, 2006 Barrier Therapeutics Announces Fourth Quarter and Year End 2005 ... Feb 27, 2006 Juvenile and adult acne Feb 23, 2006 Connetics Names Freddie Park Vice President, Intellectual Property ... Feb 6, 2006 Traditional Medicine For Acne And Its Side Effects Feb 10, 2006 Options for Adult Acne Feb 7, 2006 Seven steps to turn back time Feb 13, 2006 Use Of A Microsponge in Drug Delivery Systems Feb 6, 2006 Barrier Therapeutics to Present at Roth Capital Partners ... Feb 14, 2006 FDA Approves Vusion Ointment for the Treatment of Diaper ... Feb 17, 2006 Obagi Skin Care Products are the #1 Skin Care Line Recommended by ... Feb 16, 2006 Help fighting a double-whammy Jan 27, 2006 Connetics Names Freddie Park Vice President, Intellectual Property ... Feb 6, 2006 Options for Adult Acne Feb 7, 2006 Use Of A Microsponge in Drug Delivery Systems Feb 6, 2006 Makeover 911 : Dealing with post-New Year breakouts Jan 12, 2006 Connetics Acquires PediaMed Sales Organization; Enters Pediatric ... Jan 10, 2006 Doctors fear acne drug rules go too far Jan 30, 2006 AP Pharma Completes Financing for up to $30 Million; Sells Royalty ... Jan 18, 2006 Twitching eye likely signals eyestrain, not diet problem Jan 16, 2006 Anti-Aging Skincare: Load on Vitamins! Jan 16, 2006 Study This Jan 7, 2006 Other information Indication For relief and prevention of bronchospasm due to asthma; Emphysema; Chronic bronchitis Pharmacology Albuterol, a moderately selective beta(2)-receptor agonist similar in structure to terbutaline, is widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases. The R-isomer, levalbuterol, is responsible for bronchodilation while the S-isomer increases bronchial reactivity. Mechanism Of Action Albuterol is a beta(2)-adrenergic agonist. It stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that Albuterol increases cAMP production by activating adenylate cyclase, and the actions of albuterol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentrations leads to a smooth muscle relaxation. Increased intracellular cyclic AMP concentrations also cause an inhibition of the release of mediators from mast cells in the airways. Drug Category Adrenergic beta-Agonists; Tocolytic Agents; Bronchodilator Agents; ATC:R03AC Brand Names/Synonyms AH 3365; Accuneb; Aerolin; Albuterol; Albuterol Sulfate; Albuterol Sulfate Hfa; Asmaven; Broncovaleas; Cetsim; Cobutolin; Ecovent; Loftan; Proventil; Proventil Inhaler; Proventil-Hfa; Rotahaler; Salbulin; Salbutamol; Salbutamol Free Base; Salbutamol Sulfate; Salbutamol Sulphate; Salbutard; Salbutine; Salbuvent; Solbutamol; Sultanol; Venetlin; Ventalin Inhaler; Ventolin; Ventolin Hfa; Ventolin Inhaler; Ventolin Rotacaps; Volma; Volmax; Xopenex; Xopenex Hfa Dosage Forms ORAL SOLUTION; SYRUP; TABLETS; EXTENDED-RELEASE TABLETS; INJECTION (Intramuscular, Intravenous) Absorption Systemic absorption is rapid following aerosol administration Interactions -->Interactions for Albuterol: Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with albuterol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol on the vascular system may be potentiated. Beta-Blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as VENTOLIN Inhalation Aerosol, but may produce severe bronchospasm in patients with asthma. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics: The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics. Digoxin: Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol.
|
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |